Cite
HARVARD Citation
Li, J. et al. (2022). Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep). European journal of cancer. pp. 1-9. [Online].